Gain Therapeutics (NASDAQ:GANX) Given New $6.00 Price Target at Roth Capital

Gain Therapeutics (NASDAQ:GANX) had its price objective decreased by Roth Capital from $7.00 to $6.00 in a report issued on Wednesday,Benzinga reports. Roth Capital currently has a buy rating on the stock.

Separately, HC Wainwright reiterated a “buy” rating and issued a $8.00 target price on shares of Gain Therapeutics in a research note on Thursday, July 3rd. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, Gain Therapeutics presently has an average rating of “Buy” and a consensus price target of $7.83.

Gain Therapeutics Stock Performance

GANX stock opened at $1.55 on Wednesday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 2.22 and a current ratio of 2.22. The stock has a market cap of $46.61 million, a P/E ratio of -2.46 and a beta of 0.10. The firm has a 50 day simple moving average of $1.69 and a 200 day simple moving average of $1.91. Gain Therapeutics has a 52 week low of $0.95 and a 52 week high of $3.19.

Gain Therapeutics (NASDAQ:GANX) last posted its earnings results on Tuesday, August 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.02). Research analysts anticipate that Gain Therapeutics will post -1 earnings per share for the current fiscal year.

Institutional Trading of Gain Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of GANX. Geode Capital Management LLC raised its stake in Gain Therapeutics by 2.9% during the 2nd quarter. Geode Capital Management LLC now owns 290,462 shares of the company’s stock valued at $523,000 after purchasing an additional 8,251 shares during the last quarter. Bridgeway Capital Management LLC acquired a new position in Gain Therapeutics during the 4th quarter valued at $65,000. Northern Trust Corp raised its stake in Gain Therapeutics by 88.2% during the 4th quarter. Northern Trust Corp now owns 84,586 shares of the company’s stock valued at $183,000 after purchasing an additional 39,642 shares during the last quarter. Kovitz Investment Group Partners LLC acquired a new position in Gain Therapeutics during the 1st quarter valued at $91,000. Finally, Marshall Wace LLP raised its stake in Gain Therapeutics by 41.0% during the 2nd quarter. Marshall Wace LLP now owns 276,433 shares of the company’s stock valued at $498,000 after purchasing an additional 80,407 shares during the last quarter. 11.97% of the stock is currently owned by institutional investors and hedge funds.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.